MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

  • Manu Prasad
  • , Jonathan Zorea
  • , Sankar Jagadeeshan
  • , Avital B. Shnerb
  • , Sooraj Mathukkada
  • , Jebrane Bouaoud
  • , Lucas Michon
  • , Ofra Novoplansky
  • , Mai Badarni
  • , Limor Cohen
  • , Ksenia M. Yegodayev
  • , Sapir Tzadok
  • , Barak Rotblat
  • , Libor Brezina
  • , Andreas Mock
  • , Andy Karabajakian
  • , Jérôme Fayette
  • , Idan Cohen
  • , Tomer Cooks
  • , Irit Allon
    • Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G.T. Morris, Pierre Saintigny, Moshe Elkabets

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science